Targeted treatment of migrating partial seizures of infancy with quinidine - PubMed (original) (raw)
Case Reports
doi: 10.1002/ana.24229. Epub 2014 Jul 26.
Affiliations
- PMID: 25042079
- DOI: 10.1002/ana.24229
Case Reports
Targeted treatment of migrating partial seizures of infancy with quinidine
David Bearden et al. Ann Neurol. 2014 Sep.
Abstract
Migrating partial seizures of infancy is an early onset epileptic encephalopathy syndrome that is typically resistant to treatment. The most common cause is a gain of function mutation in the potassium channel KCNT1. The antiarrhythmic drug quinidine is a partial antagonist of KCNT1 and hence may be a candidate drug for treatment of this condition. We report the case of a child with migrating partial seizures of infancy secondary to an activating mutation in KCNT1 treated with quinidine. Treatment with quinidine was correlated with a marked reduction in seizure frequency and improved psychomotor development.
© 2014 American Neurological Association.
Comment in
- A channel for precision diagnosis and treatment in genetic epilepsy.
Poduri A. Poduri A. Ann Neurol. 2014 Sep;76(3):323-4. doi: 10.1002/ana.24243. Ann Neurol. 2014. PMID: 25092618 No abstract available. - Ineffective quinidine therapy in early onset epileptic encephalopathy with KCNT1 mutation.
Chong PF, Nakamura R, Saitsu H, Matsumoto N, Kira R. Chong PF, et al. Ann Neurol. 2016 Mar;79(3):502-3. doi: 10.1002/ana.24598. Epub 2016 Feb 12. Ann Neurol. 2016. PMID: 26748457 No abstract available. - Reply.
Bearden D, DiGiovine M, Dlugos D, Goldberg E. Bearden D, et al. Ann Neurol. 2016 Mar;79(3):503-4. doi: 10.1002/ana.24597. Epub 2016 Feb 12. Ann Neurol. 2016. PMID: 26749505 No abstract available.
Similar articles
- Quinidine in the treatment of KCNT1-positive epilepsies.
Mikati MA, Jiang YH, Carboni M, Shashi V, Petrovski S, Spillmann R, Milligan CJ, Li M, Grefe A, McConkie A, Berkovic S, Scheffer I, Mullen S, Bonner M, Petrou S, Goldstein D. Mikati MA, et al. Ann Neurol. 2015 Dec;78(6):995-9. doi: 10.1002/ana.24520. Epub 2015 Nov 18. Ann Neurol. 2015. PMID: 26369628 Free PMC article. - Quinidine therapy and therapeutic drug monitoring in four patients with KCNT1 mutations.
Yoshitomi S, Takahashi Y, Yamaguchi T, Oboshi T, Horino A, Ikeda H, Imai K, Okanishi T, Nakashima M, Saitsu H, Matsumoto N, Yoshimoto J, Fujita T, Ishii A, Hirose S, Inoue Y. Yoshitomi S, et al. Epileptic Disord. 2019 Feb 1;21(1):48-54. doi: 10.1684/epd.2019.1026. Epileptic Disord. 2019. PMID: 30782581 - Ineffective quinidine therapy in early onset epileptic encephalopathy with KCNT1 mutation.
Chong PF, Nakamura R, Saitsu H, Matsumoto N, Kira R. Chong PF, et al. Ann Neurol. 2016 Mar;79(3):502-3. doi: 10.1002/ana.24598. Epub 2016 Feb 12. Ann Neurol. 2016. PMID: 26748457 No abstract available. - KCNT1 mutations in seizure disorders: the phenotypic spectrum and functional effects.
Lim CX, Ricos MG, Dibbens LM, Heron SE. Lim CX, et al. J Med Genet. 2016 Apr;53(4):217-25. doi: 10.1136/jmedgenet-2015-103508. Epub 2016 Jan 6. J Med Genet. 2016. PMID: 26740507 Review. - Does age affect response to quinidine in patients with KCNT1 mutations? Report of three new cases and review of the literature.
Abdelnour E, Gallentine W, McDonald M, Sachdev M, Jiang YH, Mikati MA. Abdelnour E, et al. Seizure. 2018 Feb;55:1-3. doi: 10.1016/j.seizure.2017.11.017. Epub 2017 Dec 23. Seizure. 2018. PMID: 29291456 Review.
Cited by
- Lipophilic compounds restore function to neurodevelopmental-associated KCNQ3 mutations.
Edmond MA, Hinojo-Perez A, Efrem M, Yi-Chun L, Shams I, Hayoz S, de la Cruz A, Perez Rodriguez ME, Diaz-Solares M, Dykxhoorn DM, Luo YL, Barro-Soria R. Edmond MA, et al. Commun Biol. 2024 Sep 19;7(1):1181. doi: 10.1038/s42003-024-06873-4. Commun Biol. 2024. PMID: 39300259 Free PMC article. - KCNE4 is a crucial host factor for Orf virus infection by mediating viral entry.
Sun J, Ding Y, Zhou Q, Kalds P, Han J, Zhang K, Wei Y, Wu W, Wang X, Zheng W. Sun J, et al. Virol J. 2024 Aug 8;21(1):181. doi: 10.1186/s12985-024-02454-3. Virol J. 2024. PMID: 39118175 Free PMC article. - Efficacy of anti-seizure medications and alternative therapies (ketogenic diet, CBD, and quinidine) in KCNT1-related epilepsy: A systematic review.
Gras M, Bearden D, West J, Nabbout R. Gras M, et al. Epilepsia Open. 2024 Aug;9(4):1176-1191. doi: 10.1002/epi4.12975. Epub 2024 Jun 22. Epilepsia Open. 2024. PMID: 39093319 Free PMC article. Review. - New epilepsy therapies in development.
Klein P, Kaminski RM, Koepp M, Löscher W. Klein P, et al. Nat Rev Drug Discov. 2024 Sep;23(9):682-708. doi: 10.1038/s41573-024-00981-w. Epub 2024 Jul 22. Nat Rev Drug Discov. 2024. PMID: 39039153 Review. - KCNT1 Channel Blockers: A Medicinal Chemistry Perspective.
Di Matteo F, Mancuso F, Turcio R, Ciaglia T, Stagno C, Di Chio C, Campiglia P, Bertamino A, Giofrè SV, Ostacolo C, Iraci N. Di Matteo F, et al. Molecules. 2024 Jun 20;29(12):2940. doi: 10.3390/molecules29122940. Molecules. 2024. PMID: 38931004 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources